Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome

Bone Marrow Transplant. 2018 Jan;53(1):94-96. doi: 10.1038/bmt.2017.211. Epub 2017 Nov 13.

Authors

V Wais¹, L Kündgen², S R Bohl¹, S von Harsdorf¹, R F Schlenk¹, K Döhner¹, V Teleanu¹, L Bullinger¹, T M Nguyen¹, K Drognitz², J-C Moulin², M Binnenhei², M Bentz², H Döhner¹, D Bunjes¹, F Kuchenbauer¹, M Ringhoffer²

Affiliations

¹ Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
² Department of Internal Medicine III, Municipal Hospital of Karlsruhe, Karlsruhe, Germany.

PMID: 29131153
DOI: 10.1038/bmt.2017.211

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carmustine / pharmacology
Carmustine / therapeutic use*
Comorbidity
Female
Hematopoietic Stem Cell Transplantation / methods*
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / pathology
Male
Melphalan / pharmacology
Melphalan / therapeutic use*
Neoplasm Staging
Transplantation Conditioning / methods*
Transplantation, Homologous / methods*
Vidarabine / analogs & derivatives*
Vidarabine / pharmacology
Vidarabine / therapeutic use

Substances

Vidarabine
fludarabine
Melphalan
Carmustine